Medicines & Healthcare products Regulatory Agency

MHRA
Regulating Medicines and Medical Devices

Nilesh Patil
npatil@Morningsidehealthcare.com

MHRA
10 South Colonnade
London
E14 4PU
United Kingdom
www.gov.uk/mhra

22nd March 2022

Dear Nilesh Patil,

FOI 22/510

Thank you for your email, dated 2nd March 2022, in which you requested:

"the RMP of Revlimid 2.5 mg, hard capsules, EU/1/07/391/005+007"

We can confirm that the MHRA holds a copy of the requested RMP.

Information that has been redacted is exempt under Section 40 (Personal Information) or Section 43 (Commercial Interests) of the Freedom of Information (FOI) Act and is therefore withheld.

Section 40 provides that personal information may be exempt from release where to do so would contravene data protection principles. Section 43 provides that information will be exempt from release where to do so would or would be likely to prejudice commercial interests. Furthermore, we do not believe that there is an overriding public interest in disclosing the redacted information in this instance.

We hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Please remember to quote the reference number above in any future communications.

Yours sincerely,

FOI Team,
Vigilance and Risk Management of Medicines Division

ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, 4-T, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF